ArticleComputational and structural biotechnology journal2026
Comparative Analysis of Pathology Foundation Models for Automated Detection of Tertiary Lymphoid Structures in Hematoxylin-and-Eosin-Stained Digital Pathology Images.
Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC.Thoracic cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tertiary lymphoid structures (TLSs) are observed in solid tumors and are associated with improved immunotherapy outcomes, yet their dynamic nature makes TLS identification in clinical samples challenging. Pathology foundation models have recently emerged as powerful tools in computational pathology. In this study, we developed a computational approach to identifying TLSs across cancer types using pathology foundation models, with ImageNet-pretrained ResNet50 as a baseline. Models were applied to hematoxylin and eosin images from pancreatic ductal adenocarcinoma (PDAC) and head and neck squamous cell carcinoma (HNSCC) from The Cancer Genome Atlas and a licensed Real-World Evidence cohort. TLS status was evaluated using both pathologist annotations and transcriptomic-signature-based labels. Pathologist-identified TLS-positive tumors showed higher TLS signature expression in both diseases. Among the models assessed, PLIP and CTransPath demonstrated strong performance in PDAC (area under the curve = 0.94 and 0.89), whereas all models struggled in HNSCC, likely reflecting greater tumor microenvironment heterogeneity. Despite effectively detecting TLSs in PDAC, foundation models performed poorly when predicting transcriptomic-signature-based outcomes in both PDAC and HNSCC. This discrepancy suggests that transcriptomic TLS signatures may capture broader or more transient biological processes, while pathology-based assessment reflects visible TLS morphology, more closely aligned with the features foundation models learn. Overall, these findings highlight the potential of pathology foundation models for TLS detection and immune microenvironment profiling using routinely collected biosamples. However, further refinement is needed to improve performance in tumors with complex tumor microenvironment and to enable reliable prediction of transcriptomic biomarkers directly from hematoxylin and eosin slides.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.